TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22900449
Drug: Drops administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drops administration of intranasal ketamine (INK)
Study: 19455040
Drug: sugammadex 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 2.0 mg/kg
Study: 19455040
Drug: sugammadex 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 4.0 mg/kg
Study: 30221619
Drug: Brief cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive-behavioural therapy
Study: 22762867
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of tobramycin inhalation solution (TIS) for 28 days
Study: 22762867
Drug: Inhaled sodium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sodium colistimethate (2×2 millU/day) plus oral ciprofloxacin (30 mg/kg/day) for 3 months (CC)
Study: 22762867
Drug: Inhaled sodium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sodium colistimethate (CC) for 3 months
Study: 22762867
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (TIS and CC)
Study: 10485302
Drug: Separate injections
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injections (n = 215)
Study: 10485302
Drug: Single manually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single manually reconstituted injection (n = 59)
Study: 10485302
Drug: Dual-chamber syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-chamber syringe and separate injection methods
Study: 31060834
Drug: Mixed meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meals with 11 ml extra virgin olive oil
Study: 26431847
Drug: Evidence-Based Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-Based Medicine (EBM) program including a roundtable seminar on Depot Medroxy Progesterone Acetate (DMPA) and two 15 min one-on-one educational visits.
Study: 21204827
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 600 mg
Study: 1541612
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (12 immediate and 3 delayed)
Study: 1541612
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory medications
Study: 3895963
Drug: Clotrimazole 500
Normalized name: clotrimazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 500 mg single-dose treatment
Study: 3895963
Drug: Clotrimazole 200
Normalized name: clotrimazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 200 mg 3-day treatment
Study: 30707661
Drug: Alisertib 50
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib 50 mg two times per day (days 1 to 7; 21-day cycle)
Study: 30707661
Drug: Investigator-selected single-agent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-selected single-agent comparator (including intravenous pralatrexate 30 mg/m2 once per week for 6 weeks; intravenous gemcitabine 1,000 mg/m2; or intravenous romidepsin 14 mg/m2 days 1, 8, and 15; 28-day cycle)
Study: 22356118
Drug: Olanzapine monotherapy
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine monotherapy (5-20 mg/day)
Study: 18339043
Drug: Saline (Chauvin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (Chauvin Pharmaceuticals Ltd)
Study: 10595868
Drug: Stavudine-containing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine-containing triple therapies
Study: 10595868
Drug: Stavudine-containing combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine-containing combination therapies
Study: 8706777
Drug: Quinidine 200
Normalized name: quiNIDine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine 200 mg given 2 hours before codeine
Study: 8706777
Drug: Quinidine 200
Normalized name: quiNIDine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine 200 mg
Study: 8706777
Drug: Quinidine pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine pre-treatment
Study: 26472752
Drug: Obinutuzumab 1000
Normalized name: obinutuzumab 1000 MG in 40 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab 1000 mg
Study: 31603721
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (Control)
Study: 26843120
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng (5 g daily for 12 weeks)
Study: 25259743
Drug: Paricalcitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (2 μg/d for 12 weeks)
Study: 17469680
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug (not specified)
Study: 17469680
Drug: Standard agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard agent (not specified)
Study: 7594425
Drug: Cyclosporin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (5 mg/kg twice a day)
Study: 6195240
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g latamoxef
Study: 31865134
Drug: Late AED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late AED withdrawal (continued on single AED for three years before discontinuation)
Study: 29977328
Drug: Open abdomen
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open abdomen (OA) management with application of an active negative peritoneal pressure therapy (ANPPT) dressing
Study: 26884588
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with cisplatin, paclitaxel, cetuximab ± everolimus
Study: 9854662
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic regimen
Study: 7611214
Drug: Interferon alfa-n3
Normalized name: Interferon alfa-n3
DrugBank: Interferon alfa-n3 (DB00018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-n3 therapy
Study: 7611214
Drug: Platelet transfusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet transfusion, intravenous steroids, and intravenous immunoglobulin
Study: 7074750
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg every 6 hours
Study: 31332665
Drug: Core needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core needle biopsy (CNB) diagnosed papillary neoplasms (PN) with concurrent atypical ductal hyperplasia
Study: 31332665
Drug: Core needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core needle biopsy (CNB) diagnosed papillary neoplasms (PN) with concurrent atypical lobular hyperplasia/flat epithelial atypia
Study: 27960614
Drug: Short-term individual
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term individual shear rate therapy (ISRT)
Study: 26183582
Drug: Individual music
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual music therapy
Study: 23383603
Drug: Pancreatin 25,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatin 25,000 minimicrospheres (Creon 25000 MMS); 9-15 capsules/day (3 with main meals, 2 with snacks)
Study: 19249017
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) delivered in addition to treatment-as-usual (TAU)
Study: 9586892
Drug: 17-1A antibody
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17-1A antibody (900 mg total: 500 mg postoperatively followed by 4 monthly doses of 100 mg)
Study: 7988180
Drug: Terbutaline (bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (bolus, 0.25 mg; maintenance dose, 5 micrograms/min)
Study: 25196580
Drug: Pumpkin seed
Normalized name: PUMPKIN SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumpkin seed (5 g b.i.d.)
Study: 25196580
Drug: Pumpkin seed
Normalized name: PUMPKIN SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumpkin seed extract (500 mg b.i.d.)
Study: 23333088
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (2.090 g of EPA and 1.165 g of DHA)
Study: 18463627
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg infused over 30 min)
Study: 12646793
Drug: Oxymetholone TID
Normalized name: Oxymetholone
DrugBank: Oxymetholone (DB06412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetholone TID (150 mg/day)
Study: 12646793
Drug: Oxymetholone BID
Normalized name: Oxymetholone
DrugBank: Oxymetholone (DB06412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetholone BID (100 mg/day)
Study: 9346145
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral principles on a pain management program (group therapy)
Study: 9346145
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral principles on a pain management program (individual therapy)
Study: 3524463
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy plus immunotherapy with N-CWS and irradiated allogeneic AML cells
Study: 28691316
Drug: Unwaxed dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unwaxed dental floss impregnated with 2% chlorhexidine (used twice daily)
Study: 28691316
Drug: Standard unwaxed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard unwaxed dental floss (used twice daily)
Study: 27429285
Drug: Negative Pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Pressure Wound Therapy (NPWT PICO™ dressing)
Study: 12960179
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) injection
Study: 9431499
Drug: Oral condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral condition (verbal instruction only)
Study: 3531113
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of misonidazole (2.0 gm/m2) and hyperbaric oxygen (3 ATA) with irradiation (6.0 Gy in 30 fractions)
Study: 29603684
Drug: Pemafibrate (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemafibrate (0.4 mg/day, b.i.d.)
Study: 24698346
Drug: Retinol (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinol (7.5 mg RE/d)
Study: 23227789
Drug: Electro-acupuncture coupled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture coupled with conventional treatments
Study: 27354043
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments alone
Study: 20682023
Drug: Blood samples
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood samples for lipid status, hormones, insulin, and OGTT
Study: 2499185
Drug: Mannitol solution
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol solution (142 mOsm/kg)
Study: 2499185
Drug: Mannitol solution
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol solution (296 mOsm/kg)
Study: 2499185
Drug: Mannitol solution
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol solution (449 mOsm/kg)
Study: 2499185
Drug: Mannitol solution
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol solution (704 mOsm/kg)
Study: 2499185
Drug: Mannitol solution
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol solution (1481 mOsm/kg)
Study: 31418621
Drug: Topical cantharidin
Normalized name: cantharidin Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cantharidin (control group A)
Study: 8480272
Drug: 0.5 gram
Normalized name: methionine 0.5 gram ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 gram of prophylactic imipenem administered intravenously every eight hours for two weeks
Study: 2887081
Drug: Primidone (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primidone (62.5 mg X 1 up to 250 mg X 3 daily)
Study: 2887081
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 mg X 3 daily)
Study: 23804631
Drug: Asunaprevir 200
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Asunaprevir 200 mg twice daily + PEG-IFN + ribavirin
Study: 23804631
Drug: Asunaprevir 600
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Asunaprevir 600 mg twice daily + PEG-IFN + ribavirin
Study: 23804631
Drug: Asunaprevir 600
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Asunaprevir 600 mg once daily + PEG-IFN + ribavirin
Study: 16790627
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 microg/kg initial dose followed by continuous infusion of 0.5 microg.kg(‐1).h(‐1))
Study: 16790627
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 mg/kg initial dose followed by continuous infusion of 100 microg.kg(‐1).min(‐1))
Study: 12923821
Drug: DA agonist
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA agonist (lisuride=LIS)
Study: 12923821
Drug: DA antagonist
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA antagonist (fluphenazine=FLU)
Study: 8463932
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient treatment (Control)
Study: 3517475
Drug: BAY m
Normalized name: ZINC OXIDE 94 mg in 1 mL TOPICAL LOTION [Cay Skin MoBay Mineral Sunscreen Drops SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY m 1099 (25, 50, 100, 200 mg)
Study: 3517475
Drug: BAY o
Normalized name: Bay Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY o 1248 (10, 20, 40 mg)
Study: 29194765
Drug: Toceranib (TOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toceranib (TOC) 2.75 mg/kg EOD
Study: 29194765
Drug: Vinblastine (VBL)
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinblastine (VBL) 2.5 mg/m2 weekly × 4 then EOW
Study: 24836151
Drug: Control agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control agents (moral information removed)
Study: 20460548
Drug: Simvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (80 mg/d)
Study: 12625145
Drug: Simultaneous dosing
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous dosing (artesunate 200 mg/d plus mefloquine 250 mg/d from day 1 to day 3)
Study: 12625145
Drug: Sequential dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential dosing (artesunate 200 mg/d for 3 days plus mefloquine 250 mg on day 2 and 500 mg on day 3)
Study: 12412178
Drug: Morphine mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine mouthwash (MO; 14 patients)
Study: 12412178
Drug: Magic mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magic mouthwash (MG; 12 patients)
Study: 8029260
Drug: High-dose human
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose human leukocyte alpha-interferon (IFN-alpha) treatment
Study: 2929931
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 2% lignocaine
Study: 28333939
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg slow-release three times daily
Study: 23459753
Drug: 4 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 × 20 g whey protein every 3 h (INT)
Study: 23459753
Drug: 8 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 × 10 g whey protein every 1.5 h (PULSE)
Study: 23459753
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 40 g whey protein every 6 h (BOLUS)
Study: 20809354
Drug: Telephone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone administered cognitive behavioral therapy
Study: 20809354
Drug: Telephone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone administered supportive emotion‐focused therapy
Study: 19356666
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy using 'Photogem'
Study: 17123204
Drug: Robot-assisted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted treatment (all types)
Study: 12827582
Drug: Alfentanil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 10 micro g/kg
Study: 12827582
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 micro g/kg
Study: 12827582
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2 micro g/kg
Study: 10747343
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg twice daily for 5 months)
Study: 9373227
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition by central venous catheter
Study: 1539787
Drug: Oral airways
Normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral airways
Study: 21971750
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (Control group)
Study: 18474534
Drug: Early Gp
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Gp IIb-IIIa inhibitors
Study: 11794455
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen at 10 L/min through a facemask
Study: 1791060
Drug: Dextroamphetamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (5 and 10 mg orally, 1 hr prior to test)
Study: 9481526
Drug: Walnut diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut diet (78 g/d walnuts)
Study: 7990368
Drug: Multimodality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality treatment with laser
Study: 7990368
Drug: Drug monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug monotherapy (Control)
Study: 2499443
Drug: Glyburide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (15 mg/day)
Study: 25346499
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg once daily for five days followed by 15 mg or 20 mg once daily)
Study: 25346499
Drug: Dose-adjusted warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted warfarin (coadministration of aspirin 100 mg per day until achieving international normalized ratio of 1.7)
Study: 23788287
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) for thromboprophylaxis
Study: 23788287
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin for thromboprophylaxis
Study: 19597914
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod 5% cream plus Nd:YAG laser treatment
Study: 19597914
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream plus Nd:YAG laser treatment
Study: 17409018
Drug: Ribavirin, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin, 1000 mg daily (n=7)
Study: 17409018
Drug: Ribavirin, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin, 1000 mg daily + Amantadine, 200 mg daily (n=8)
Study: 17409018
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (controls, n=26)
Study: 17409018
Drug: Ribavirin and
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin and Amantadine (combined treatment)
Study: 9891831
Drug: Cibenzoline (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (130 mg twice daily)
Study: 9891831
Drug: Disopyramide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (250 mg slow release twice daily)
Study: 7636755
Drug: Remoxipride administered
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride administered at 5 different time intervals (2, 8, 12, 24, and 48 hr)
Study: 81361
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day oral DL-carnitine chloride
Study: 81361
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of carnitine
Study: 22123869
Drug: Acetaminophen administered
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen administered 30 minutes before immunization and every 4 hours thereafter for a total of 5 doses
Study: 9065537
Drug: Acetaminophen use
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen use
Study: 15349012
Drug: Venlafaxine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75 to 112.5 mg/d)
Study: 10396705
Drug: Pimobendan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan (2.5 or 5 mg daily)
Study: 7587031
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g IV cefotaxime every 12 h
Study: 7587031
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g IV ceftriaxone once daily